Pasithea Therapeutics
KTTA
6 hedge funds and large institutions have $48.9K invested in Pasithea Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
2.01% less ownership
Funds ownership: 2.88% → 0.87% (-2%)
14% less funds holding
Funds holding: 7 → 6 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
68% less capital invested
Capital invested by funds: $152K → $48.9K (-$103K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$32.2K |
| 2 |
Morgan Stanley
New York
|
+$7.39K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$59 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$140K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.94K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$256 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $35.6K | +$32.2K | +6,529 | +17,182% |
|
|
2
Morgan Stanley
New York
| $8.13K | +$7.39K | +1,500 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $3.26K | -$5.94K | -1,206 | -67% |
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
5
JP Morgan Chase
New York
| $813 | – | – | – |
|
|
6
Bank of America
Charlotte,
North Carolina
| $98 | +$59 | +12 | +200% |
|
|
ACM
7
ADAR1 Capital Management
Austin,
Texas
| – | -$140K | -27,696 | Closed |
|
|
8
Fidelity Investments
Boston,
Massachusetts
| – | -$256 | -49 | Closed |
|
KTTA Hedge Fund Activity: Q3 2024 in Review
6 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q3 2024, worth a combined $48.9K — down 68% from $152K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of KTTA and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $32.2K. The largest seller was ADAR1 Capital Management, exiting entirely with an estimated $140K sold.
- 6 institutional investors held Pasithea Therapeutics (KTTA) as of Q3 2024, down from 7 in Q2 2024.
- Funds reported $48.9K of Pasithea Therapeutics stock for Q3 2024, down 68% quarter-over-quarter.
- 1 fund opened new Pasithea Therapeutics positions in Q3 2024 and 2 closed out, a net change of -1 holder.
- The largest Pasithea Therapeutics buyer in Q3 2024 was UBS Group, an estimated $32.2K added.
- The largest Pasithea Therapeutics seller in Q3 2024 was ADAR1 Capital Management, an estimated $140K sold.
Based on aggregated 13F filings for Q3 2024.